Delivery Order SPE2DB20D3103-SPE2DB25FQ3F3
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with a contract ceiling value of $1,476.89. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025, and represents a non-set-aside, competitively awarded procurement. The contract is executed under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a contract ceiling value of $1,703.81. This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,153.55 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The contract will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 26, 2025. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $742,596.96 to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 17, 2025, and represents a non-set-aside competitive award. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance, leveraging the company's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,158.02 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. The contract was awarded on July 30, 2025, with an ultimate completion date of July 31, 2025, and employs firm fixed pricing with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this delivery order under its larger Indefinite...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $3,216.66 on August 5, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) in 3 ml vials. This competitively awarded, firm fixed-price delivery order is set to be completed by August 6, 2025, with performance conducted at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials, with a contract value of $32,445.16. This competitively awarded, firm fixed-price delivery order was issued on August 26, 2025, with an ultimate completion date of August 27, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials valued at $27,509.02. This non-competitive delivery order was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract employs firm fixed pricing and represents a continuation of AmerisourceBergen's role as a critical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials, with a ceiling value of $3,494.97. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of July 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a delivery order issued under a larger federal contract vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $33,922.83. This is a firm fixed price delivery order with no set-aside designation, issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order is to be fulfilled from the...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ3F3Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials with a ceiling value of $11,415.25. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 17, 2025, and represents performance at the vendor's Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical prime vendor agreement running through December 2026 that supplies a broad range of medications and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, has established itself as a critical federal medical procurement vendor through competitive award of multiple contracts with the DLA Medical Supply Chain. The company's extensive portfolio includes diabetes medications, neurological treatments, pain management pharmaceuticals, antibiotics, vaccines, and specialized medical supplies across multiple therapeutic domains. This particular delivery order for Ozempic, a diabetes medication, exemplifies the company's role in supplying brand-name pharmaceuticals to support Defense Health Agency and military healthcare systems globally under open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.4k | 9/16/25 |